Neoleukin Therapeutics (NLTX) executive Walkey sold 600 shares for $6,600 at $11.00 under a 10b5-1 plan
Insider transactions reported
Carl Walkey (executive at Neoleukin Therapeutics Inc., NLTX) reported that they sold 600 shares for $6,600 at $11.00 on Jun 8, 2021. After these transactions the filing shows 1,353,739 shares held directly.
- Reporting person
- Walkey Carl
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 8, 2021 | Open-market sale (S) | Common Stock1 | -600 | $11.00 | $6,600 | 1,353,739 direct |
Holdings before and after
- Common Stock: 1,354,339 to 1,353,739 direct
Footnotes from the filing
- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
FAQ
What did Walkey report in this NLTX Form 4?
Carl Walkey (executive at Neoleukin Therapeutics Inc., NLTX) reported that they sold 600 shares for $6,600 at $11.00 on Jun 8, 2021. After these transactions the filing shows 1,353,739 shares held directly.
How many NLTX shares does Walkey hold after this filing?
The filing shows 1,353,739 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this NLTX insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for NLTX
Earlier insider filings at NLTX
- Jun 7, 2021SEC Form 4: Walkey Carl sold $6,000 worth of Common Stock (600 units at $10.00), decreasing direct ownership by 0.04% to 1,354,339 units
- Jun 7, 2021SEC Form 4 filed by Neoleukin Therapeutics, Inc.
- May 26, 2021SEC Form 4: Walkey Carl sold $6,000 worth of Common Stock (600 units at $10.00), decreasing direct ownership by 0.04% to 1,354,939 units
- May 13, 2021SEC Form 4 filed by Williams Lewis T
- May 13, 2021SEC Form 4 filed by SIMPSON TODD E
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Follow NLTX and get a push notification the moment its next story breaks.